While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

After struggling with weight gain for three years, Sarah Bisacca was diagnosed with insulin resistance. Here's how she was learned to manage it.

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss study, boosting market-share gains and stock prices.

Maintaining optimal health is more important than ever in today’s fast-paced world. With the increasing prevalence of ...

A last-minute donation to a holiday auction raised over $1,100 in scholarship money for local high school students on Tuesday ...

The 29-year-old Bachelor alum revealed on the Lightweights Podcast with Joe Vulpis that his weight loss was actually so ...